X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
JZP598 (zanidatamab) is an investigational bispecific antibody that can simultaneously bind two non-overlapping epitopes of HER2, known as biparatopic binding. It is being evaluated for the treatment of HER2-positive metastatic biliary tract cancer.
Lead Product(s): Zanidatamab
Therapeutic Area: Oncology Product Name: JZP598
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2024
Details:
Through the acquisition, Jazz Pharmaceuticals will have access to Redx Pharma KRAS (Kirsten rat sarcoma virus) inhibitor program for all clinical development, regulatory, manufacturing, and commercialization activities.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Redx Pharma
Deal Size: $880.0 million Upfront Cash: $10.0 million
Deal Type: Acquisition February 07, 2024
Details:
JZP150 is an investigational small molecule selective fatty acid amide hydrolase (FAAH) inhibitor. It is being evaluated in phase 2 clinical trials for the treatment of adult patients with post-traumatic stress disorder.
Lead Product(s): JZP150
Therapeutic Area: Psychiatry/Psychology Product Name: JZP150
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2023
Details:
Epidiolex (cannabidiol) is an oral CB receptor CB1 receptor negative allosteric modulator. It is now approved for the treatment of seizures associated with Lennox-Gastaut syndrome & Dravet syndrome in patients 2 years of age and older.
Lead Product(s): Cannabidiol
Therapeutic Area: Rare Diseases and Disorders Product Name: Epidiolex
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2023
Details:
The agreement aims to discover and develop drug candidates targeting two different ion channel targets associated with neurological disorders. Autifony will lead drug discovery and preclinical development activities on the two targets.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Recipient: Autifony Therapeutics
Deal Size: $770.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 14, 2023
Details:
The collaboration aims to evaluate ZW25 (zanidatamab), Jazz's investigational HER2-targeted bispecific antibody that can simultaneously bind two non-overlapping epitopes of HER2, known as biparatopic binding, in multiple HER2-expressing cancers.
Lead Product(s): Zanidatamab
Therapeutic Area: Oncology Product Name: ZW25
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: The University of Texas MD Anderson Cancer Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 07, 2023
Details:
Enrylaze (recombinant Erwinia asparaginase) administered as intravenous infusion, which is indicated for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients.
Lead Product(s): Recombinant Erwinia Asparaginase
Therapeutic Area: Oncology Product Name: Enrylaze
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2023
Details:
JZP458 is a recombinant Erwinia asparaginase or crisantaspase that uses a Pseudomonas fluorescens expression platform.9 It is being developed for use as a component of a multi-agent chemotherapeutic regimen in the treatment of acute lymphoblastic leukemia.
Lead Product(s): Recombinant Asparaginase Erwinia Chrysanthemi-rywn
Therapeutic Area: Oncology Product Name: Rylaze
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2023
Details:
Vyxeos (daunorubicin and cytarabine) have synergistic effects at killing leukemia cells by inhibiting DNA polymerase activity, is indicated as a chemotherapy treatment option specifically indicated for the treatment of adults with newly diagnosed t-AML or AML-MRC.
Lead Product(s): Daunorubicin,Cytarabine
Therapeutic Area: Oncology Product Name: Vyxeos
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2023
Details:
Epidyolex (cannabidiol), plant-derived cannabis-based medicine which is act CB receptor agonist, administered as an oral solution, is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients 1 year of age and older.
Lead Product(s): Cannabidiol
Therapeutic Area: Rare Diseases and Disorders Product Name: Epidyolex
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
